A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam

Int J Infect Dis. 2014 Jun:23:90-3. doi: 10.1016/j.ijid.2014.01.017. Epub 2014 Apr 12.

Abstract

Background: Acinetobacter baumannii has been reported increasingly as a significant causative organism of various nosocomial infections, including hospital-acquired pneumonia (HAP). The aim of this study was to investigate the clinical characteristics of HAP induced by carbapenem-resistant A. baumannii (CRAB) in elderly patients and the in vitro antimicrobial effects of cefoperazone/sulbactam combination therapy.

Methods: Seventy-one elderly patients in the geriatric ward of the General Hospital of the People's Liberation Army (PLAGH) with CRAB-induced HAP were analyzed retrospectively. The checkerboard method was used to determine the in vitro drug sensitivity of 60 CRAB strains to antimicrobial combinations (cefoperazone/sulbactam with meropenem, minocycline, or levofloxacin). The occurrence of carbapenemase genes was detected by PCR.

Results: CRAB-induced HAP occurred mostly in patients with underlying diseases. Prior to onset, most patients had received antimicrobial therapies including broad-spectrum β-lactams, invasive mechanical ventilation, and catheterization. The 30-day survival rate was 95.1% in patients using cefoperazone/sulbactam, with or without combination with antimicrobial drugs, and 73.3% in patients not using cefoperazone/sulbactam (p<0.05). When cefoperazone/sulbactam was used in combination with minocycline, levofloxacin, and meropenem, minimum inhibitory concentrations MIC50 and MIC90 were reduced for each drug. The genes OXA-23 and OXA-51 were amplified in 96.7% of the strains, but the genes OXA-24, OXA-58, SIM, VIM, and IMP were not amplified.

Conclusions: CRAB-induced HAP occurred mostly in patients with anemia or decreased levels of serum albumin, but with elevated levels of C-reactive protein and creatinine. Cefoperazone/sulbactam in combination with minocycline, meropenem, and levofloxacin had a synergistic and additive in vitro bacteriostatic action on CRAB.

Keywords: Acinetobacter baumannii; Carbapenem; Combined drug sensitivity test; Hospital-acquired pneumonia.

MeSH terms

  • Acinetobacter baumannii / drug effects*
  • Acinetobacter baumannii / isolation & purification
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • C-Reactive Protein / metabolism
  • Carbapenems / pharmacology*
  • Cefoperazone / therapeutic use*
  • Cross Infection / drug therapy*
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial
  • Drug Synergism
  • Female
  • Humans
  • Levofloxacin / therapeutic use
  • Male
  • Meropenem
  • Microbial Sensitivity Tests
  • Middle Aged
  • Minocycline / therapeutic use
  • Pneumonia, Bacterial / drug therapy*
  • Retrospective Studies
  • Sulbactam / therapeutic use*
  • Thienamycins / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Drug Combinations
  • Thienamycins
  • Levofloxacin
  • Cefoperazone
  • C-Reactive Protein
  • Meropenem
  • Minocycline
  • Sulbactam